We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+36.49%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$364M
AUM Growth
+$126M
Cap. Flow
+$47.9M
Cap. Flow %
13.16%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$75.1M
2
NKTX icon
Nkarta
NKTX
+$20.8M
3
MLYS icon
Mineralys Therapeutics
MLYS
+$2.74M

Top Sells

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$50.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$163M 44.83%
2,346,630
-800,000
-25% -$50.7M
CRSP icon
2
CRISPR Therapeutics
CRSP
$5.23B
$71.5M 19.64%
+1,048,951
New +$75.1M
SPRY icon
3
ARS Pharmaceuticals
SPRY
$591M
$41M 11.26%
4,012,903
– –
NKTX icon
4
Nkarta
NKTX
$167M
$36M 9.9%
3,333,333
+2,000,000
+150% +$20.8M
DSGN icon
5
Design Therapeutics
DSGN
$915M
$26.3M 7.22%
6,526,476
– –
MLYS icon
6
Mineralys Therapeutics
MLYS
$2.41B
$26M 7.15%
2,016,822
+222,222
+12% +$2.74M

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
FFL
Flat Footed LLC Wilson, Wyoming $920M AUM 86.47% 1-Year Est. Return

SR One Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, SR One Capital Management held 6 positions worth $364M, up 53% from $238M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

SR One Capital Management deployed $47.9M of net new capital in Q1 2024, opening 1 new position and adding to 2 existing holdings. Its largest new stake was CRISPR Therapeutics: 1,048,951 shares worth $71.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Arcellx, an estimated $50.7M trimmed.

  • SR One Capital Management's largest Q1 2024 buy was CRISPR Therapeutics: 1,048,951 shares worth $71.5M.
  • SR One Capital Management added most to Nkarta in Q1 2024, an estimated $20.8M increase.
  • SR One Capital Management's biggest Q1 2024 reduction was Arcellx, cutting an estimated $50.7M.
  • SR One Capital Management's ten largest holdings make up 100% of its $364M portfolio in Q1 2024.
  • SR One Capital Management opened 1 new position and closed 0 in Q1 2024.
  • SR One Capital Management's portfolio value rose 53% quarter-over-quarter to $364M.

Based on SR One Capital Management's 13F filing for Q1 2024, filed 13 May 2024.